455 related articles for article (PubMed ID: 10458008)
41. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission.
Valentini L; Schaper L; Buning C; Hengstermann S; Koernicke T; Tillinger W; Guglielmi FW; Norman K; Buhner S; Ockenga J; Pirlich M; Lochs H
Nutrition; 2008; 24(7-8):694-702. PubMed ID: 18499398
[TBL] [Abstract][Full Text] [Related]
42. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
[TBL] [Abstract][Full Text] [Related]
43. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype.
Seow CH; Stempak JM; Xu W; Lan H; Griffiths AM; Greenberg GR; Steinhart AH; Dotan N; Silverberg MS
Am J Gastroenterol; 2009 Jun; 104(6):1426-34. PubMed ID: 19491856
[TBL] [Abstract][Full Text] [Related]
44. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease.
Vitali R; Stronati L; Negroni A; Di Nardo G; Pierdomenico M; del Giudice E; Rossi P; Cucchiara S
Am J Gastroenterol; 2011 Nov; 106(11):2029-40. PubMed ID: 21788990
[TBL] [Abstract][Full Text] [Related]
45. [Assessment of usefulness of anti-Saccharomyces cerevisiae and anti-neutrophil cytoplasmic antibodies in patients with unspecific inflammatory bowel diseases].
Mokrowiecka A; Gasiorowska A; Małecka-Panas E
Pol Merkur Lekarski; 2004; 17 Suppl 1():22-6. PubMed ID: 15603341
[TBL] [Abstract][Full Text] [Related]
46. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease.
Valentini L; Wirth EK; Schweizer U; Hengstermann S; Schaper L; Koernicke T; Dietz E; Norman K; Buning C; Winklhofer-Roob BM; Lochs H; Ockenga J
Nutrition; 2009 Feb; 25(2):172-81. PubMed ID: 18849144
[TBL] [Abstract][Full Text] [Related]
47. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients.
Bodelier AG; Pierik MJ; van den Heuvel T; Bovee-Oudenhoven IM; de Boer E; Hameeteman W; Masclee AA; Jonkers D
Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):902-9. PubMed ID: 24915490
[TBL] [Abstract][Full Text] [Related]
48. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease.
Reinders CA; Jonkers D; Janson EA; Stockbrügger RW; Stobberingh EE; Hellström PM; Lundberg JO
Scand J Gastroenterol; 2007 Oct; 42(10):1151-7. PubMed ID: 17852876
[TBL] [Abstract][Full Text] [Related]
49. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease.
Koutroubakis IE; Xidakis C; Karmiris K; Sfiridaki A; Kandidaki E; Kouroumalis EA
Eur J Clin Invest; 2006 Feb; 36(2):127-32. PubMed ID: 16436095
[TBL] [Abstract][Full Text] [Related]
50. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity.
Abad E; Tural C; Mirapeix E; Cuxart A
J Autoimmun; 1997 Apr; 10(2):175-80. PubMed ID: 9185879
[TBL] [Abstract][Full Text] [Related]
51. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.
Henriksen M; Jahnsen J; Lygren I; Stray N; Sauar J; Vatn MH; Moum B;
Gut; 2008 Nov; 57(11):1518-23. PubMed ID: 18566104
[TBL] [Abstract][Full Text] [Related]
52. Inflammatory bowel diseases: controversies in the use of diagnostic procedures.
Vucelic B
Dig Dis; 2009; 27(3):269-77. PubMed ID: 19786751
[TBL] [Abstract][Full Text] [Related]
53. [Initial clinical experiences with a simplified analytic method for fecal alpha-1-antitrypsin].
Fischbach W; Deubel M; Boege F; Mössner J
Z Gastroenterol; 1991 Dec; 29(12):650-4. PubMed ID: 1771947
[TBL] [Abstract][Full Text] [Related]
54. [Fecal excretion and the clearance of alpha 1-antitrypsin in patients with Crohn's disease].
López A; Hinojosa J; Miralles A; Primo J; Bermúdez JD
Rev Esp Enferm Dig; 1993 Apr; 83(4):235-9. PubMed ID: 8494651
[TBL] [Abstract][Full Text] [Related]
55. Malnutrition in inflammatory bowel disease patients in northern India: frequency and factors influencing its development.
Ghoshal UC; Shukla A
Trop Gastroenterol; 2008; 29(2):95-7. PubMed ID: 18972769
[TBL] [Abstract][Full Text] [Related]
56. Fecal radioiodide excretion following intravenous injection of 131-I-albumin and 125-I-immunoglobulin G in chronic inflammatory bowel disease. An aid to topographic diagnosis.
Jarnum S; Jensen KB
Gastroenterology; 1975 Jun; 68(6):1433-44. PubMed ID: 1132626
[TBL] [Abstract][Full Text] [Related]
57. Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis.
Husain N; Tokoro K; Popov JM; Naides SJ; Kwasny MJ; Buchman AL
J Clin Gastroenterol; 2013 Mar; 47(3):246-51. PubMed ID: 23269308
[TBL] [Abstract][Full Text] [Related]
58. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea.
Fine KD; Ogunji F; George J; Niehaus MD; Guerrant RL
Am J Gastroenterol; 1998 Aug; 93(8):1300-5. PubMed ID: 9707055
[TBL] [Abstract][Full Text] [Related]
59. Random fecal alpha-1-antitrypsin concentration in children with gastrointestinal disease.
Thomas DW; Sinatra FR; Merritt RJ
Gastroenterology; 1981 Apr; 80(4):776-82. PubMed ID: 6970702
[TBL] [Abstract][Full Text] [Related]
60. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
Ciećko-Michalska I; Fedak D; Mach T
Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
